Cell & Gene Therapy

The advent of cell and gene therapies has ushered in a bold new era of medicine, one where previously incurable diseases now have treatment options.

As you work to bring the promise of these innovative therapies into the clinic, MaxCyte® is here to accelerate your journey to success.

Designed with cell and gene therapy in mind

Over 20 years ago, MaxCyte’s technology was designed to overcome cell and gene therapy development barriers.

Today we partner with researchers who are actively assessing these therapies in clinical trials for treatment of genetic disease, hematologic malignancies, solid tumors and more. We are proud to be a part of many of the pioneering studies in this field.

MaxCyte_Illustrations_FAS + Customer + Instrument
MaxCyte_Illustrations_T-cell

How we enable cell and gene therapy development

Over the many years we’ve dedicated to optimizing and advancing electroporation, we’ve perfected an innovative technology that achieves key goals to streamline cell and gene therapy development:

  • Highly efficient delivery of diverse payloads
    • Nucleic acids
    • Proteins
    • Small molecules
  • High cell viability after electroporation
  • Seamless scalability with the same technology and general protocols from concept to clinic
  • Simplified workflow with MaxCyte’s Electroporation Buffer

Research applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Viral Vector Production

Transfect adherent or suspension cells to produce a variety of viral vectors.

Leverage MaxCyte’s pioneering expertise in cell therapy to accelerate product development and de-risk manufacturing

Employing our clinically-validated electroporation platform you can expedite process optimization and seamlessly transition to the clean room.

Our meticulously designed consumables maximize cell recovery to help achieve therapeutic dose.

With partnerships established with 25 leading biotech companies, our unmatched scientific and regulatory support help you navigate technical and regulatory hurdles.

MaxCyte_Illustrations_Clinician-+-Patient

Resources

image@2x
Poster
Scalable Electroporation of Adult Keratinocytes with Multiplexed CRISPR Ribonucleoproteins for the Development of Novel Cell Therapeutics.
Electroporation-of-a-Non-Integrative-DNA-Nanovector-for-Efficient,-Semi-Automated,-GMP-Manufacturing-of-CAR-T-Cell-Therapies@2x-min
Scientific Brief
Electroporation of a Non-Integrative DNA Nanovector for Efficient, Semi-Automated, GMP Manufacturing of CAR T Cell Therapies.
CRISPR-Electroporation-of-T-Cells-Improves-Treatment-in-Patients@2x-min
Application Note
CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer.
View All Cell Therapy Development Resources

Ready to learn how we can simplify your cell and gene therapy development?

Answers are just a click away!

1M5A3478@2x